Accessibility StatementSkip Navigation RAMAT-GAN, Israel, Nov. 17, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced today results from its joint research with Virginia Commonwealth University (VCU) evaluating Aramchol's effect on overcoming drug resistance in gastrointestinal (GI) cancers. The collaboration is based on breakthrough findings pub ...

Core Insights - Vistin Pharma ASA reported a revenue increase in Q3 2025, reaching MNOK 109, up from MNOK 106 in Q3 2024, driven by a 10% higher sales volume [1] - Year-to-date revenue for 2025 is MNOK 342, an 8% increase from MNOK 316 in the same period last year [1] - The company's EBITDA for Q3 2025 was MNOK 28, slightly down from MNOK 29 in Q3 2024, impacted by lower global metformin prices [1] - Year-to-date EBITDA for 2025 stands at MNOK 89, a 16% increase from MNOK 77 in YTD 2024 [1] - Net profit for Q3 2025 was MNOK 18.5, compared to MNOK 16.6 in the previous year [2] - The company achieved an all-time high production volume of 1,600 MT of metformin in the quarter [2] Financial Performance - Q3 2025 revenue: MNOK 109, up 2.8% from Q3 2024 [1] - YTD 2025 revenue: MNOK 342, an 8% increase from YTD 2024 [1] - Q3 2025 EBITDA: MNOK 28, down from MNOK 29 in Q3 2024 [1] - YTD 2025 EBITDA: MNOK 89, up 16% from YTD 2024 [1] - Q3 2025 net profit: MNOK 18.5, compared to MNOK 16.6 in Q3 2024 [2] Production and Operations - All-time high production volume of metformin: 1,600 MT in Q3 2025 [2]

Summary of Longevity Industry Insights Industry Overview - The longevity market is a multi-billion dollar industry, encompassing high-tech diagnostics, gene modulation, anti-aging medications, and lifestyle apps aimed at extending healthy life spans [14][20][94] - The global revenue from longevity products is projected to grow from $20 billion to over $60 billion by 2035, indicating a significant market opportunity [97] Key Insights - **Market Drivers**: The longevity movement is driven by research institutions, investors, and consumers seeking healthier aging solutions. Notable tech billionaires like Jeff Bezos and Peter Thiel are heavily investing in this sector [97][94] - **Research and Development**: Institutions like the Cologne Excellence Cluster for Aging and Aging-Associated Diseases (CECAD) are at the forefront of aging research, focusing on understanding the biological mechanisms of aging and developing preventive measures [96][102] - **Innovative Approaches**: Promising research includes the use of drugs like Rapamycin and Metformin, which have shown potential in extending lifespan in animal studies [123][124] - **Start-up Landscape**: Numerous start-ups are emerging in the longevity space, such as Refoxy Pharma, which focuses on the FOXO3 gene to combat age-related diseases [126][130] Emerging Trends - **Cultural Shift**: There is a growing belief that aging is not an inevitable decline but a process that can be managed and potentially reversed through scientific advancements [95][101] - **Investment in Longevity**: Venture capital firms like Apollo Health Ventures and Kizoo Technology Capital are actively funding longevity research and start-ups, indicating strong financial backing for innovative solutions [135] - **Skepticism and Caution**: Despite the hype, many products marketed as longevity solutions lack scientific validation. Experts caution consumers to be wary of unproven claims, especially in the cosmetic and supplement sectors [142][121] Noteworthy Developments - **Conferences and Collaborations**: Events like the Zuzalu conference in Montenegro bring together global leaders in the longevity movement to discuss innovative approaches and potential collaborations [94][95] - **Regulatory Challenges**: Obtaining regulatory approval for preventive medications remains a significant hurdle, as current frameworks primarily support treatments for existing conditions rather than preventive measures [130] Conclusion - The longevity industry is rapidly evolving, with significant investments and research efforts aimed at extending healthy life spans. However, consumers should approach marketed solutions with caution, as many claims are not yet substantiated by rigorous scientific evidence. The future of this industry will likely depend on successful research outcomes and the ability to translate findings into practical applications.

Both rapamycin and metformin have drawn the attention of the “live for ever” brigade. But what does the science say about their effectiveness? https://t.co/FfnxuNij4GIllustration: Cristina Spanò https://t.co/pE6psv9Mbi ...